BetaGlue has enrolled the first patient treated with BAT-90 in its First-in-Human trials, taking radiotherapy inside solid tumours

The first clinicalfindingshave shown that BAT-90makes it possible to treat onlythe area where the tumour is located, while avoiding the surrounding tissues, so as to combine treatmentefficacy and patient safety

BetaGlue Technologieshasenrolledthe first patientin a clinical trialwithBAT-90, the company’s cancer radiotherapy platform. The first clinical findings have shown thatBAT-90 makes it possible to treat only the area where the tumour is located, while avoiding the surroundingtissues, so as to combine treatment efficacy and patient safety.

Theclinical trialinliver cancerpatient has been coordinated byProfessor MalkhazMizandariat theNew Hospitals in Tbilisi(Georgia), an international centre of excellenceaffiliated with Thomas Jefferson University in Philadelphia (USA).

BAT-90consists of aβradiation-emitting biocompatible matrix, delivered to patientsviaapercutaneous injection: the Yttrium-90-labelled microspheres present inside thematrix are injected into the tumour and, as the carrier takes only120 seconds to reach full polymerisation, they are retained exclusively in the injected area. Thisprevents the microspheres from spreading to surrounding tissues or organs, so as to release their radiation energy only to the target tumour. Inthis way, avery low radioactive doseis needed, much lower than the one used with conventionalradio-metabolic treatments, thus enhancing treatment efficacy and patient safety.

BAT-90opens up important horizons in oncology, bringing benefits to both patients andhealthcare systems. Indeed, BAT-90 is atherapeutic nuclear medicinesolution that is extremelyprecise(it only targets the tumour area),personalised(calibrated to the patient’sclinical situation),rapid(a single injection reaching full polymerisation in just a fewminutes) andsafe(the radiation energy is released where needed, avoiding exposure ofsurrounding tissues and organs and thus minimizing any risk to either patients or healthcareprofessionals).

Dr. Antonino Amato, BetaGlue Technologies’ CEO/CMO, said: “The confirmation in this first patient ofthe previous findings from the pre-clinical studies with BAT-90 opens up tremendous perspectives totherapeutic nuclear medicine in oncology, which will hopefully lead to improved outcomes and better qualityof life for patients affected by several types of cancer”.

Dr. Riccardo Palmisano, BetaGlue Technologies’ Executive Chairman, commented: “The beginning of thefirst clinical trial with BAT-90 with a positive confirmation of efficacy and safety is a very meaningfulstep for patients with solid tumours, for oncologists and radiotherapists treating them, and for BetaGlueTechnologies, which today takes a major leap forward in creating value for the shareholders who believe inour project”.